Literature DB >> 15228733

Patterns of treatment and resource utilization in the treatment of external genital warts in England and Wales.

Paul C Langley1, David J White, Susan M Drake.   

Abstract

Our objective was to identify patterns of treatment and resources used in achieving complete clearance of external genital warts (EGWs) A retrospective case note review was carried out at six genitourinary medicine (GUM) clinics in the UK. Case notes from 2366 patients presenting with EGWs were reviewed and 1200 patients with complete episodes of care were identified. Analysis showed that staff-applied therapy dominated treatment practice but there was considerable diversity in treatment modalities across study sites. The average number of visits was 5.71 visits for males: 6.25 visits for females but a substantial minority of patients attended significantly in excess of these averages. Approximately two-thirds of patients failed to achieve complete clearance of warts with their initial therapy. There is little consistency in treatment patterns of care for EGWs across the sites studied. Initial therapy choices are largely ineffective, requiring changes in treatment modality and multiple clinic visits. Increased utilization of patient-applied therapies might result in increased cost effectiveness.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15228733     DOI: 10.1258/0956462041211199

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN: 0956-4624            Impact factor:   1.359


  2 in total

Review 1.  Economic and humanistic burden of external genital warts.

Authors:  Adam J N Raymakers; Mohsen Sadatsafavi; Fawziah Marra; Carlo A Marra
Journal:  Pharmacoeconomics       Date:  2012-01       Impact factor: 4.981

2.  Hospitalization for diseases attributable to human papillomavirus in the Veneto Region (North-East Italy).

Authors:  Vincenzo Baldo; Silvia Cocchio; Alessandra Buja; Tatjana Baldovin; Patrizia Furlan; Chiara Bertoncello; Mario Saia
Journal:  BMC Infect Dis       Date:  2013-10-05       Impact factor: 3.090

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.